论文部分内容阅读
目的：研究α１Ａ受体阻断剂——盐酸坦索罗辛对不同体积良性前列腺增生症（ＢＰＨ）的疗效。方法：对６０例症状性ＢＰＨ按前列腺体积大小分成三组：体积＜３０ｍｌ１３例，体积３０～４０ｍｌ２５例，体积＞４０ｍｌ２２例。分别给予盐酸坦索罗辛０．２ｍｇ口服，１次／ｄ，治疗观察６周。结果：三组患者主观症状明显改善；国际前列腺症状评分（ＩＰＳＳ）分别降低４１．１％、３９．８％、３９．２％；最大尿流率（ＭＦＲ）和平均尿流率（ＡＦＲ）分别提高２５．０％、２３．４％、２７．９％和２５．５％、２０．３％、２５．５％。其中４７例残余尿（ＰＶＲ）下降５１．６％（Ｐ＜０．０１）。三组之间ＩＰＳＳ评分，ＭＦＲ和ＡＦＲ变化率统计学上无显著性差异。盐酸坦索罗辛对所有患者前列腺体积、血压、脉搏无明显影响（Ｐ值均＞０．０５）。结论：盐酸坦索罗辛对不同体积ＢＰＨ患者的自觉症状、客观体征和生活质量有明显的改善作用，无明显严重副反应
Objective: To investigate the effect of tamsulosin hydrochloride, an α1A receptor blocker, on different volumes of benign prostatic hyperplasia (BPH). Methods: Sixty cases of symptomatic BPH were divided into three groups according to the size of the prostate: 13 cases in volume <30ml, 25 cases in volume 30 ~ 40ml and 22 cases in volume> 40ml. Tamsulosin hydrochloride 0.2mg was given orally once daily for 6 weeks. Results: The subjective symptoms of the three groups were significantly improved. The International Prostate Symptom Score (IPSS) decreased by 41.1%, 39.8% and 39.2%, respectively. The maximum flow rate (MFR) and the average flow rate (AFR) Increase by 25.0%, 23.4%, 27.9% and 25.5%, 20.3% and 25.5% respectively. Among them, 47 cases of residual urine (PVR) decreased by 51.6% (P <0.01). IPSS score, MFR and AFR rate of change between the three groups showed no statistically significant difference. Tamsulosin hydrochloride had no significant effect on prostate volume, blood pressure and pulse rate in all patients (P> 0.05). Conclusion: Tamsulosin hydrochloride can significantly improve the symptoms, objective signs and quality of life in patients with different volume of BPH without obvious serious side effects